TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1273596

Group type: EXPERIMENTAL
Intervention: Stimulant medication (methylphenidate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30699155

Group type: EXPERIMENTAL
Intervention: Optimized-debunking training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual training
Number of subjects: 0
Study: 25792303

Group type: EXPERIMENTAL
Intervention: Early individualised manipulative rehabilitation (twice a week for 4 weeks, 30 minutes per session)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Active control care
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Early individualised manipulative rehabilitation
Number of subjects: 21
Study: 24682612

Group type: EXPERIMENTAL
Intervention: Natural conception
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Factor V Leiden mutation
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Subsequent pregnancy after RM diagnosis
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Previous miscarriages
Number of subjects: 251
Study: 24933974

Group type: EXPERIMENTAL
Intervention: Standard treatment with psychotropic medication plus valemidin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard basic therapy plus valemidin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard basic therapy
Number of subjects: 0
Study: 19464000

Group type: EXPERIMENTAL
Intervention: ICSI with piezoelectric stimulation (Group IA)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard ICSI procedure (Group IB)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: ICSI with piezoelectric activation (Group II)
Number of subjects: 71
Study: 17516115

Group type: EXPERIMENTAL
Intervention: 7-Fr straight plastic stent
Number of subjects: 63

Group type: COMPARATOR
Intervention: 10-Fr straight plastic stent
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study: 17170609

Group type: EXPERIMENTAL
Intervention: Carvedilol CR 20 mg
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Carvedilol CR 40 mg
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Carvedilol CR 80 mg
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 14578787

Group type: EXPERIMENTAL
Intervention: Medial pedicle/vertical pattern reduction (group II)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Wise pattern reduction (group I)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 208
Study: 10766415

Group type: EXPERIMENTAL
Intervention: Vitamin C (Celin 500 mg) and Vitamin E (Evion 400 mg) for 90 days along with tamoxifen (10 mg twice a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen treatment alone
Number of subjects: 0
Study: 9364758

Group type: EXPERIMENTAL
Intervention: Expressive writing (writing deepest thoughts and feelings about the exam)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (writing about a trivial topic)
Number of subjects: 0
Study: 7828255

Group type: EXPERIMENTAL
Intervention: Doxacurium 30 micrograms.kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pancuronium 70 micrograms.kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neostigmine 40 micrograms.kg‐1 (with atropine)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neostigmine (various doses)
Number of subjects: 60
Study: 3287972

Group type: EXPERIMENTAL
Intervention: Cefotetan (single 2 g preoperative dose)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Cefoxitin (multiple 2 g perioperative doses)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 289

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Cefotetan and Cefoxitin
Number of subjects: 289
Study: 30239963

Group type: EXPERIMENTAL
Intervention: RAxML
Number of subjects: 3950

Group type: EXPERIMENTAL
Intervention: ASTRAL
Number of subjects: 3950

Group type: EXPERIMENTAL
Intervention: NJst
Number of subjects: 3950

Group type: EXPERIMENTAL
Intervention: SVDquartets
Number of subjects: 3950

Group type: EXPERIMENTAL
Intervention: Filtering by information content
Number of subjects: 3950
Study: 27730670

Group type: EXPERIMENTAL
Intervention: European Guidelines publication
Number of subjects: 27942

Group type: EXPERIMENTAL
Intervention: Regional recommendations for apixaban
Number of subjects: 27942

Group type: EXPERIMENTAL
Intervention: Regional recommendations for dabigatran
Number of subjects: 27942

Group type: EXPERIMENTAL
Intervention: No specific recommendation for rivaroxaban
Number of subjects: 27942

Group type: EXPERIMENTAL
Intervention: Overall trend
Number of subjects: 27942
Study: 28285317

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 100
Study: 24070456

Group type: EXPERIMENTAL
Intervention: Individualised pro-active fall prevention strategies from the clinical researcher
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 20826875

Group type: EXPERIMENTAL
Intervention: Cortical grey matter volume
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Volumes of left lateral frontal orbital gyrus
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Volumes of right lateral frontal orbital gyrus
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Left lateral frontal orbital gyrus volume
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pittsburgh Compound B (PIB) imaging
Number of subjects: 100
Study: 19220913

Group type: EXPERIMENTAL
Intervention: Self-management with telemonitoring
Number of subjects: 478

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 478
Study: 17270055

Group type: EXPERIMENTAL
Intervention: 16 mg OROS hydromorphone under fasting conditions
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 16 mg OROS hydromorphone under fed conditions
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 16 mg OROS hydromorphone under fasting conditions with naltrexone 50-mg block
Number of subjects: 30
Study: 14982571

Group type: EXPERIMENTAL
Intervention: Remifentanil concentration of 3 ng ml(‐1) until incision
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Remifentanil concentration of 5 ng ml(‐1) for intubation
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Remifentanil concentration of 10 ng ml(‐1) during intra-abdominal surgery
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Remifentanil concentration of 5-7 ng ml(‐1) during closure
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: High remifentanil concentration
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Intraoperative remifentanil concentrations
Number of subjects: 61
Study: 11681648

Group type: EXPERIMENTAL
Intervention: TAA delivered via pMDI with Azmacort spacer (75 microg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: TAA delivered via pMDI without spacer (230 microg)
Number of subjects: 10
Study: 8652714

Group type: EXPERIMENTAL
Intervention: Autoimplantation technique
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Podophyllin regimen
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Humoral and cell mediated immune responses
Number of subjects: 50
Study: 1385913

Group type: EXPERIMENTAL
Intervention: Indomethacin for the first 5 postoperative days (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Thymopentin perioperatively and on the second and fourth postoperative days (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional therapy (group C)
Number of subjects: 60
Study: 6429359

Group type: EXPERIMENTAL
Intervention: 5 days of starvation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 5 days of refeeding with carbohydrate (n=6)
Number of subjects: 14

Group type: COMPARATOR
Intervention: 5 days of refeeding without carbohydrate (n=6)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Starvation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition in cachectic patients
Number of subjects: 14
Study: 30773555

Group type: EXPERIMENTAL
Intervention: Polylactide (PLA) scaffolds
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Polycaprolactone (PCL) scaffolds
Number of subjects: 20
Study: 29316895

Group type: EXPERIMENTAL
Intervention: Repetitive sensory stimulation (RSS)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Sham RSS (control)
Number of subjects: 71
Study: 26979999

Group type: EXPERIMENTAL
Intervention: Movement pain and movement fatigue
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Movement pain and fatigue
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Movement fatigue
Number of subjects: 94
Study: 24875670

Group type: EXPERIMENTAL
Intervention: Light-intensity walking at 3.2 km/h every 20 min
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Moderate-intensity walking at between 5.8 and 6.4 km/h every 20 min
Number of subjects: 19

Group type: COMPARATOR
Intervention: Uninterrupted sitting
Number of subjects: 19
Study: 22997495

Group type: EXPERIMENTAL
Intervention: 100 U BoNT‐A
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 200 U BoNT‐A
Number of subjects: 34
Study: 19239933

Group type: EXPERIMENTAL
Intervention: Mechanical preparation of the colon (MPC)
Number of subjects: 193

Group type: COMPARATOR
Intervention: No mechanical preparation of the colon (No-MPC)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Colocolic anastomosis (MPC)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Colorectal anastomosis (MPC)
Number of subjects: 193
Study: 17606560

Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment
Number of subjects: 360
Study: 15356500

Group type: EXPERIMENTAL
Intervention: Haas appliance
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Hyrax appliance
Number of subjects: 19

Group type: COMPARATOR
Intervention: Both appliances
Number of subjects: 19
Study: 11427643

Group type: EXPERIMENTAL
Intervention: Low-flux haemodialysis (Low-HD, n=10)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High-flux haemodialysis (High-HD, n=10)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Online haemodiafiltration (HDF, n=10)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Online haemofiltration (HF, n=9)
Number of subjects: 39
Study: 9886106

Group type: EXPERIMENTAL
Intervention: Praziquantel (Thai Government Pharmaceutical Organization) 40 mg/kg
Number of subjects: 95

Group type: COMPARATOR
Intervention: Biltricide 40 mg/kg
Number of subjects: 95
Study: 9700743

Group type: EXPERIMENTAL
Intervention: CCK-4 (0.5 mg/h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2916453

Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lean children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obese children after 6 months of treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lean children after 6 months of treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups after 6 months
Number of subjects: 0
Study: 343992

Group type: EXPERIMENTAL
Intervention: 1200 mg tolmetin daily for 2 weeks
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 150 mg ketoprofen daily for 2 weeks after 1 week on placebo
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo for 1 week
Number of subjects: 64

Group type: COMPARATOR
Intervention: 600 mg tolmetin daily for 2 weeks
Number of subjects: 64
Study: 31823525

Group type: COMPARATOR
Intervention: Tropifexor (LJN452) 10-3000 µg single ascending doses (SAD)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Tropifexor (LJN452) 10-100 µg multiple ascending doses (MAD)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Tropifexor (LJN452) 300 µg with a high-fat meal
Number of subjects: 95

Group type: COMPARATOR
Intervention: Tropifexor (LJN452) vs placebo in obese subjects
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Tropifexor (LJN452)
Number of subjects: 95
Study: 31099803

Group type: EXPERIMENTAL
Intervention: Nurse-led intervention (individual counseling and pamphlet)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 28705995

Group type: EXPERIMENTAL
Intervention: Nocturnal continuous positive airway pressure (CPAP) device
Number of subjects: 0

Group type: COMPARATOR
Intervention: HRCT imaging
Number of subjects: 0
Study: 25895447

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with 5-fluorouracil plus cisplatin
Number of subjects: 164
Study: 23935969

Group type: EXPERIMENTAL
Intervention: Ixabepilone 40 mg/m² every 3 weeks (Group A)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ixabepilone 20 mg/m² on days 1, 8, and 15 every 4 weeks (Group B)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study: 21871987

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 1433

Group type: COMPARATOR
Intervention: No mechanical bowel preparation (No MBP)
Number of subjects: 1433
Study: 19046971

Group type: EXPERIMENTAL
Intervention: Tube feeding
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combined feedings (tube feeding + oral feeding)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combined feedings
Number of subjects: 15
Study: 16891292

Group type: EXPERIMENTAL
Intervention: bezafibrate (400 mg/d) for 6 months
Number of subjects: 186
Study: 14763913

Group type: EXPERIMENTAL
Intervention: GH replacement therapy (GHRT) at a starting dose of 0.45 IU (0.15 mg)/day, increased to 0.9 IU (0.30 mg)/day in month 2, and maintained at 2 IU (0.66 mg)/day
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (healthy controls matched for age, education, and sex)
Number of subjects: 14
Study: 11740294

Group type: EXPERIMENTAL
Intervention: 8 weeks of supervised circuit training (combined aerobic and resistance exercise)
Number of subjects: 19
Study: 8989178

Group type: EXPERIMENTAL
Intervention: Oral and enteral ofloxacin-amphotericin B (group B)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Oral and enteral polymyxin E-tobramycin-amphotericin B (group C)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Conventional antibiotic regimen (control group A)
Number of subjects: 660
Study: 8120739

Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa (20/5 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo (20 mg)
Number of subjects: 10
Study: 3314221

Group type: EXPERIMENTAL
Intervention: Bivalent, live attenuated intranasally administered influenza A vaccine
Number of subjects: 55

Group type: COMPARATOR
Intervention: Inactivated, parenterally administered influenza A vaccine
Number of subjects: 55
Study: 29502281

Group type: EXPERIMENTAL
Intervention: Cognitive narrative therapy intervention (four sessions: decision, subjectivation, metaphorization, projecting)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 91
Study: 27796912

Group type: EXPERIMENTAL
Intervention: Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg/day
Number of subjects: 1747

Group type: COMPARATOR
Intervention: Tiotropium (TIO) 18 mcg/day
Number of subjects: 1747
Study: 26132682

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 150

Group type: COMPARATOR
Intervention: Minimal Acupuncture
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo Acupuncture
Number of subjects: 150
Study: 22812251

Group type: EXPERIMENTAL
Intervention: Alpha-keto/amino acid supplemented low protein diet
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional diabetes diet
Number of subjects: 23
Study: 20735827

Group type: EXPERIMENTAL
Intervention: Mental practice intervention (6 weeks, delivered by physiotherapists and occupational therapists)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mandatory part of the intervention
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Optional part of the intervention
Number of subjects: 16
Study: 18719318

Group type: EXPERIMENTAL
Intervention: Aspirin + thienopyridine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 32
Study: 15942767

Group type: EXPERIMENTAL
Intervention: Concurrent inspiratory and expiratory muscle training (CRMT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham CRMT
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CRMT (differing intensities)
Number of subjects: 34
Study: 12759480

Group type: EXPERIMENTAL
Intervention: Lung-volume-reduction surgery
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Lung-volume-reduction surgery (subgroup with predominantly upper-lobe emphysema and low exercise capacity)
Number of subjects: 1218

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 1218
Study: 10484859

Group type: EXPERIMENTAL
Intervention: Morphine to Methadone ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydromorphone to Methadone ratio
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of pain syndromes
Number of subjects: 0
Study: 8984866

Group type: EXPERIMENTAL
Intervention: (1.5 x ED95 mivacurium) + (0.5 x ED95 rocuronium)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (1 x ED95 mivacurium) + (1 x ED95 rocuronium)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (0.5 x ED95 mivacurium) + (1.5 x ED95 rocuronium)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (2 x ED95 mivacurium)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (2 x ED95 rocuronium)
Number of subjects: 0

Group type: COMPARATOR
Intervention: mivacurium alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: rocuronium alone
Number of subjects: 0
Study: 1752109

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.003 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.007 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.02 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Alprazolam (all doses)
Number of subjects: 6
Study: 6242491

Group type: EXPERIMENTAL
Intervention: Intensive care interventions in the perinatal period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive care in Level 3 hospitals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perinatal interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neonatal intensive care
Number of subjects: 0
Study: 31470899

Group type: EXPERIMENTAL
Intervention: 2000 IU/d cholecalciferol (vitamin D3)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 4000 IU/d cholecalciferol (vitamin D3)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 90
Study: 27487783

Group type: COMPARATOR
Intervention: Treatment condition 1 (computer delivered risk assessment and feedback, nurse brief advice)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Treatment condition 2 (all elements of Treatment condition 1 plus biochemical feedback of infant SHS exposure)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Treatment condition 1
Number of subjects: 39

Group type: COMPARATOR
Intervention: Treatment condition 2
Number of subjects: 39
Study: 25458804

Group type: EXPERIMENTAL
Intervention: Care programme for challenging behaviour (education package and structured assessment tools)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Control measurements (no intervention)
Number of subjects: 380
Study: 24524866

Group type: EXPERIMENTAL
Intervention: Sedation with midazolam and fentanyl
Number of subjects: 73

Group type: COMPARATOR
Intervention: No sedation
Number of subjects: 73
Study: 22588253

Group type: EXPERIMENTAL
Intervention: Active THC (2.8% THC)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Expectancy of having smoked THC
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Expectancy of smoking THC in combination with active THC
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Active drug and expectancy
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 20850848

Group type: EXPERIMENTAL
Intervention: Moyo chart
Number of subjects: 61

Group type: COMPARATOR
Intervention: Lookup tables
Number of subjects: 61
Study: 18161677

Group type: EXPERIMENTAL
Intervention: Brachial-basilic arteriovenous fistula (BB-AVF)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Prosthetic brachial-antecubital forearm loop access (PTFE)
Number of subjects: 27
Study: 15899950

Group type: EXPERIMENTAL
Intervention: L-folic acid (7.5 mg/d)
Number of subjects: 20
Study: 12789968

Group type: EXPERIMENTAL
Intervention: Product 2 (cetylpyridinium chloride)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Product 1 (essential oils)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Product 4 (chlorine dioxide plus zinc)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Product 3 (placebo)
Number of subjects: 99
Study: 9814729

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 microg b.d.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 34
Study: 7544219

Group type: EXPERIMENTAL
Intervention: Human recombinant IGF-I (2 x 80 micrograms/kg body weight subcutaneously)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 2689790

Group type: EXPERIMENTAL
Intervention: bioMérieux kit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serono kit
Number of subjects: 0

Group type: COMPARATOR
Intervention: micronized progesterone administration
Number of subjects: 0
Study: 320111

Group type: EXPERIMENTAL
Intervention: Oral zinc sulphate as adjuvant treatment
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Plasma zinc levels in patients with idiopathic ulcerative colitis or proctitis
Number of subjects: 51
Study: 31919527

Group type: EXPERIMENTAL
Intervention: Whey Protein (WP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Collagen Protein (CP)
Number of subjects: 22
Study: 30448778

Group type: EXPERIMENTAL
Intervention: Online training counselling on safe sport participation every 3 months
Number of subjects: 357

Group type: COMPARATOR
Intervention: Control group (no online training counselling)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 357

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 357